Last reviewed · How we verify
NCT02771054
Tenofovir Alafenamide Fumarate (TAF) Effect on Residual Intrathecal Immune Activation
Phase 4 trial testing TAF/FTC in HIV in 22 participants. Completed in 15 July 2018.
15 July 2018
Quick facts
| Lead sponsor | Göteborg University |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 22 |
| Start date | 2 May 2016 |
| Primary completion | 15 July 2018 |
| Estimated completion | 15 July 2018 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- TAF/FTC — full drug profile →
Conditions studied
- HIV — all drugs for HIV →
Sponsor
Göteborg University
Who can join
18 and older, any sex, with HIV. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Many HIV-infected individuals on effective antiretroviral therapy with suppressed HIV RNA levels in blood as well as in cerebrospinal fluid have signs of low-level intrathecal inflammation. Our aim is to study if changing the nucleoside backbone in an antiretroviral regimen can decrease the residual intrathecal immune activation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02771054
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HIV
Currently open trials in the same condition.
- NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
- NCT07221214 — GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · recruiting
- NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV · NA · recruiting
- NCT07390474 — Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA i · Phase 1 · recruiting
- NCT07390955 — A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 · Phase 1 · recruiting
Other Göteborg University trials
Trials by the same sponsor.
- NCT07260604 — HIFEM for Incontinence After Menopause High-Intensity Focused Electromagnetic (HIFEM) · NA · not yet recruiting
- NCT07401420 — Life Sustaining Treatments in Critically Ill Children · not yet recruiting
- NCT07213245 — Metabolic Effects of Short-term Ultra-processed Food Intake (MEST-UPF) · NA · recruiting
- NCT07178405 — Effects of Meal Characteristics on Appetite · NA · completed
- NCT07172841 — Non-invasive Diagnostics of Shunt Obstruction in Adult Hydrocephalus · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02771054 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Göteborg University
- Last refreshed: 5 November 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02771054.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing